Akeso, Inc. (09926.HK) received an increase of 60,000 ordinary shares by Zhang Peng, valued at approximately HK$5.2458 million.

As reported on June 16, according to filings disclosed by the Hong Kong Stock Exchange (HKEX) on the same day, Zhang Peng acquired 60,000 ordinary shares of Akeso, Inc. (09926.HK) on June 12 at an average price of HK$87.43 per share, amounting to approximately HK$5.2458 million. Following this acquisition, Zhang Peng’s total shareholding increased to 32,568,100 shares, raising his long position stake from 3.53% to 3.54%. Image source: HKEX Equity Ownership Disclosures What is an equity ownership disclosure? Under HKEX requirements, substantial shareholders—individuals or entities holding 5% or more of a listed company’s shares—are required to disclose their interests in the company’s shares. Listed companies’

Futu NewsJun 16 17:06

Akeso, Inc. (09926.HK) received an increase of 100,000 ordinary shares held by Xia Yu, valued at approximately HK$8.7564 million.

According to a filing disclosed by the Hong Kong Stock Exchange on June 16, Xia Yu purchased 100,000 ordinary shares of Akeso, Inc. (09926.HK) on June 11 at an average price of HK$87.5635 per share, for a total value of approximately HK$8.7564 million. Following this acquisition, Xia Yu’s latest shareholding stands at 230 million shares, increasing his beneficial ownership stake from 24.97% to 24.99%. Additional information: Boxes 24 - 27: The Gemstone Living Trust purchased 100,000

Futu NewsJun 16 17:06

Akeso, Inc. (09926.HK) received an acquisition of 100,000 ordinary shares by Xia Yu, valued at approximately HK$9.4067 million.

According to a filing disclosed by the Hong Kong Stock Exchange on June 16, Xia Yu acquired 100,000 ordinary shares of Akeso, Inc. (09926.HK) on June 15 at an average price of HK$94.0665 per share, for a total value of approximately HK$9.4067 million. Following this acquisition, Xia Yu’s latest shareholding stands at 230 million shares, increasing her beneficial ownership stake from 24.99% to 25.00%. Supplementary information: Boxes 24 - 27: The Gemstone Living Trust purchased 100,000

Futu NewsJun 16 17:06

Akeso, Inc. (09926.HK): Ivosidenib IO 2.0 OS Shows Strong Positive Results, Further Validating Global Value

The ASCO conference reported a strong positive overall survival (OS) hazard ratio (HR) of 0.66 from the HARMONi-6 trial. ① In the ITT population, compared with tislelizumab plus chemotherapy, ivonescimab plus chemotherapy significantly reduced the risk of death by 34%.

Soochow SecuritiesJun 16 13:47

Guotai Haitong: Citing the high景qi (favorable conditions) in the innovative pharmaceuticals sector, strong fundamentals among listed companies, and low valuations, we remain bullish on the development of China's innovative pharmaceuticals industry.

The Innovative Drug Index has fallen back to the level seen before the previous rally in innovative drug stocks began (May 2025), highlighting its attractive valuation.

Zhitong FinanceJun 16 07:14

Billions in Share Buybacks to Stabilize Markets? As Stock Prices Remain Weak, Leading Pharmaceutical Firms Launch a 'Valuation Defense Campaign'

① Amid sustained downward pressure on share prices, several pharmaceutical companies—including Sino Biopharm, Akeso, and Wuxi Apptec—have successively announced share repurchase or management buy-in plans; ② Industry insiders believe that such repurchases can help restore market sentiment, but a meaningful re-rating of the sector will still depend on the consistent realization of commercialization and global expansion capabilities.

cls.cnJun 15 17:06